🧠Neurotech · 20372026-11-19
A Cortical BCI For Vision Restoration (Neuralink Blindsight Class) Enters Commercial Use, Providing Low-resolution Sight To Blind Individuals.2037

A Cortical BCI For Vision Restoration (Neuralink Blindsight Class) Enters Commercial Use, Providing Low-resolution Sight To Blind Individuals.

Record: 2026-10-31 · sha256: 91faef0a69ce99a9 · Resolution source: tesorb.com · Tesorb - Neuralink Clinical Trials Tracker

A Cortical BCI For Vision Restoration (Neuralink Blindsight Class) Enters Commercial Use, Providing Low-resolution Sight To Blind Individuals.

A Cortical BCI For Vision Restoration (Neuralink Blindsight Class) Enters Commercial Use, Providing Low-resolution Sight To Blind Individuals. Probability: 42%. Confidence Level: Medium.

Will Neuralink Blindsight Restore Vision For Blind People By 2037?

Cortical brain-computer interfaces (BCIs) for vision restoration, such as Neuralink's Blindsight, aim to restore sight by directly stimulating the visual cortex. This article examines the timeline, technical hurdles, and approval prospects for these devices.

What Is The Current Status Of Neuralink Blindsight?

Neuralink's Blindsight device received FDA Breakthrough Device designation in September 2024. This status accelerates development and review. Human trials are planned to begin in 2026. The device targets the visual cortex, bypassing the eyes and optic nerve, to create phosphene-based low-resolution vision. According to Neuralink's announcements, the goal is to help even congenitally blind individuals perceive shapes and movement.

Why Is Visual Cortex Stimulation More Difficult Than Motor BCI?

Motor BCIs read signals from the motor cortex to control a cursor or limb. Visual restoration requires writing complex spatial-temporal patterns into the visual cortex. This is a fundamentally different problem. It demands:

  • Different surgical targeting: Inserting electrodes into the visual cortex (V1) carries risks of seizures and tissue damage.
  • Complex signal encoding: The brain's visual processing relies on lateral inhibition and edge detection. Simple electrical pulses produce "phosphenes" (dots of light) that flicker and fade unpredictably.
  • Custom outcome metrics: Unlike motor control (e.g., clicking a button), vision success requires measuring object recognition, navigation, and reading ability.

Research from the Illinois Institute of Technology and Baylor College of Medicine (2018-2021) showed that intracortical microstimulation in V1 can evoke stable, localized phosphenes in blind humans. However, the resolution was limited to about 150 electrodes, producing roughly a 10x10 pixel grid. This is far from natural vision.

What Technical Problems Must Be Solved Before 2037?

Three main technical barriers remain:

1. Tissue response: Electrodes get encapsulated by glial scars, reducing signal quality over months. Neuralink's thin, flexible threads may mitigate this, but long-term data in humans is absent.

2. Phosphene stability: Users report that phosphenes flicker or disappear after seconds. The visual cortex habituates to constant stimulation. Researchers at the Netherlands Institute for Neuroscience are testing closed-loop stimulation that adjusts pulse frequency in real time to maintain perception.

3. Power and wireless data rate: A high-resolution implant (e.g., 1000 channels) needs to transmit 10-20 Mbps wirelessly through the skull. Neuralink's N1 chip handles 1024 channels, but the bandwidth for visual patterns is untested.

What Is The Regulatory And Commercial Timeline?

Motor BCIs (like Synchron's Stentrode or Neuralink's Telepathy) are expected to receive FDA approval around 2028-2029. Visual BCIs will likely follow 5-7 years later. This is because:

  • Phase I safety trials (2026-2028) will enroll only 5-10 participants.
  • Phase II efficacy trials (2029-2032) will need to demonstrate meaningful vision gains (e.g., reading 20 characters per minute or avoiding obstacles).
  • Phase III pivotal trials (2033-2035) will compare against assistive technologies like the OrCam MyEye.

Given the FDA's Breakthrough Device pathway, a Premarket Approval (PMA) application could be submitted in 2036. Commercial launch in 2037 is plausible but aggressive. The primary risk is a delay in Phase II due to adverse events (e.g., seizures or infection).

What Would Widespread Clinical Use Look Like?

If approved, the initial market would be limited to profoundly blind adults (estimated 1.5 million in the US). The device would not restore normal vision but provide "visual assist" for navigation and object detection. Reimbursement would require Medicare coverage, which typically takes 2-3 years post-approval. Thus, "wide clinical use" by 2037 means at least 500-1000 implanted patients, not mass adoption.

Frequently Asked Questions

1. Can Blindsight Help People Born Blind?

Yes, the visual cortex develops even in congenital blindness, though its wiring is atypical. Neuralink's Blindsight aims to stimulate this area directly. Early animal studies show that naive visual cortex can learn to interpret artificial signals, but human data is pending. The 2026 trial will include both acquired and congenital blindness cases.

2. What Is The Expected Visual Resolution In 2037?

Most experts predict a 32x32 pixel grid (1024 electrodes) providing enough detail to read large text, recognize faces, and navigate rooms. This is roughly equivalent to a 1990s monochrome screen. Achieving 20/80 vision (legal blindness threshold) would require 10,000+ electrodes, which is beyond current power and surgical limits.

3. How Does This Compare To Other Visual Prosthetics Like Argus II?

Argus II (retinal implant) was withdrawn from the market in 2022 due to poor sales and limited efficacy. It required functional retinal ganglion cells, so it failed for most blind patients. Cortical BCIs bypass the eye entirely, making them applicable to glaucoma, diabetic retinopathy, and optic nerve damage. However, cortical implants carry higher surgical risk (intracranial surgery) versus Argus's eye surgery.

Loading…

Related Predictions

All predictions